Avacta Engages Peel Hunt as New Adviser
Company Announcements

Avacta Engages Peel Hunt as New Adviser

Avacta Group plc (GB:AVCT) has released an update.

Avacta Group plc, a life sciences company involved in developing cancer treatments and diagnostics, has appointed Peel Hunt LLP as its Nominated Adviser and sole broker. The company is known for its two proprietary platforms, pre|CISION™ and Affimer®, targeting oncology with a focus on enhancing the precision and reducing the toxicity of drug therapies. Avacta’s leading drug, AVA6000, has entered Phase 1 studies and is demonstrating promising improvements over traditional treatments.

For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAvacta Group Advances with Targeted Cancer Therapies
TipRanks UK Auto-Generated NewsdeskAvacta Group Unveils Promising Cancer Therapy Advances
TipRanks UK Auto-Generated NewsdeskAvacta Group PLC Issues New Shares Amid Strategic Shift
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App